- Sharp Services is expanding its autoinjector and pen assembly network in the U.S. and Europe, adding new assembly lines and equipment to support injectable programs from clinical development through commercialization.
- The company is also expanding temperature-controlled storage, including more than 4,400 additional pallet locations at its Macungie, Pennsylvania facility and increased cold storage capacity in Bethlehem.
Sharp Services, a pharmaceutical packaging, clinical trial services and sterile manufacturing company, is expanding its autoinjector and pen assembly network to support injectable programs through development and commercialization. The expansion builds on the company’s previously announced $20 million investment and includes additional assembly capacity and 2-8°C temperature-controlled storage.
At its Macungie, Pennsylvania facility, Sharp is adding a low-speed assembly line capable of producing two autoinjectors or pen devices per minute, expected to be operational in the first quarter of 2027. A mid-speed line capable of 50 autoinjectors per minute is expected to follow in the first quarter of 2028. The site has also added two temperature-controlled storage units providing more than 4,400 additional pallet locations for sensitive biotech drug products, with occupancy expected in the fourth quarter of 2026.
Sharp is also adding a low-speed assembly line at its Bethlehem, Pennsylvania facility for autoinjector and pen programs spanning clinical development through low-volume commercial supply, particularly for rare disease and orphan drugs. The line will assemble up to two devices per minute and is expected online in the first quarter of 2027. The facility has also completed an expansion of its 2-8°C and -20°C cold rooms, doubling storage capacity and adding a 2-8°C packaging suite.
In Europe, Sharp is expanding its capabilities in Belgium with assembly equipment ranging from two devices per minute to 100 devices per minute. The expansion also includes functional testing and a fully automatic 2-8°C warehouse. Sharp said the investments are intended to provide scalable support for drug delivery device programs across development and commercial supply, including through Sharp-invested production lines or the integration of client-owned equipment.
“Injectable assembly and packaging programs have different requirements as they move from the clinic to commercialization, and our clients need a partner that can support that progression.”
Jeff Benedict, Chief Commercial Officer of Sharp
